Stockholders' Equity |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2022 | |||
| Stockholders' Equity [Abstract] | |||
| Stockholders' Equity |
At-The-Market Program
On February 4, 2021, Ocuphire filed a Form S-3 shelf registration under the Securities Act of 1933 which was declared effective by the SEC on February 12, 2021 (the “2021 Shelf”) under which the Company may offer
and sell, from time to time in its sole discretion, securities having an aggregate offering price of up to $125 million. In
connection with the 2021 Shelf, on March 11, 2021, Ocuphire entered into a sales agreement with JonesTrading Institutional Services LLC (“JonesTrading”) under which the Company may offer and sell, from time to time at its sole discretion,
to or through JonesTrading, acting as agent and/or principal, shares of its common stock having an aggregate offering price of up to $40
million (the “2021 ATM”). During the three months ended March 31, 2022, 336,544 shares of common stock were sold under the
2021 ATM for gross proceeds in the amount of $1.2 million before deducting issuance expenses, including the placement agent’s
fees, legal and accounting expenses, in the amount of $35,000. There were no sales of common stock under the 2021 ATM during the three-month period ended March 31, 2021.
Registered Direct Offering
On June 4, 2021, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (“AGP”). Pursuant to the terms of the placement agency agreement, AGP on June 8, 2021 sold an aggregate of
3,076,923 shares of the Company’s common stock and warrants to purchase 1,538,461 shares of the Company’s common stock (the “RDO Warrants”). The RDO Warrants have an exercise price of $6.09 per share, are exercisable from the initial issuance date of June 8, 2021, and will expire five years following the initial issuance date. As of March 31, 2022, 1,538,461
RDO Warrants were outstanding.
|